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Abstract
Purpose: To determine whether functional proteomics improves breast cancer
classification and prognostication and can predict pathological complete response
(pCR) in patients receiving neoadjuvant taxane and anthracycline-taxane-based
systemic therapy (NST).
Methods: Reverse phase protein array (RPPA) using 146 antibodies to proteins
relevant to breast cancer was applied to three independent tumor sets. Supervised
clustering to identify subgroups and prognosis in surgical excision specimens from a
training set (n = 712) was validated on a test set (n = 168) in two cohorts of patients
with primary breast cancer. A score was constructed using ordinal logistic regression
to quantify the probability of recurrence in the training set and tested in the test set.
The score was then evaluated on 132 FNA biopsies of patients treated with NST to
determine ability to predict pCR.
Results: Six breast cancer subgroups were identified by a 10-protein biomarker panel
in the 712 tumor training set. They were associated with different recurrence-free
survival (RFS) (log-rank p = 8.8 E-10). The structure and ability of the six subgroups to
predict RFS was confirmed in the test set (log-rank p = 0.0013). A prognosis score
constructed using the 10 proteins in the training set was associated with RFS in both
training and test sets (p = 3.2E-13, for test set). There was a significant association
between the prognostic score and likelihood of pCR to NST in the FNA set (p =
0.0021).
Conclusion: We developed a 10-protein biomarker panel that classifies breast cancer
into prognostic groups that may have potential utility in the management of
patients who receive anthracycline-taxane-based NST.
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Introduction
To inform decisions about therapy, it is necessary to have a better understanding of
the molecular mechanisms underlying the heterogeneity of breast cancer. Transcrip-
tional profiling revealed that breast cancer represents at least six molecular subtypes
associated with different clinical features [1-3]. However, comprehensive analysis of
breast cancer transcriptomes does not capture all levels of biological complexity;
important additional information may reside in the proteome [4-7].
Proteins are the direct effectors of cellular function. Protein levels and function
depend on translation as well as on post-translational modifications [6], which influ-
ence protein stability and activity [7]. Although many proteins have been studied as
prognostic and predictive factors in breast cancer, only three alter current practice:
estrogen receptor (ER), progesterone receptor (PR) and HER2. Thus, a systematic
study of expression and activation of multiple proteins and signaling pathways may
facilitate more accurate classification and prediction in breast cancer.
Neoadjuvant systemic therapy (NST) allows for in vivo assessment of chemosensitiv-
ity. Attaining a pathologic complete response (pCR) following NST provides a surro-
gate marker for improved long-term outcome. Conversely, patients with residual breast
cancer after NST are at increased risk for recurrence and may have therapy-resistant
disease [8-12].
The objective of this study was to apply functional proteomics to breast cancer clas-
sification and prognosis, and to develop a predictor of pCR in a group of primary
tumor samples obtained by fine needle aspirations (FNA) from patients who subse-
quently received NST.
Material and Methods
Tumor tissues
Three sets of frozen breast cancer tissues were used: Training set (n = 712) was col-
lected at M. D. Anderson Cancer Center (MDACC), Hospital Clinico Universitario de
Valencia, Spain, University of British Columbia, Vancouver, BC, and Baylor College of
Medicine, Houston, TX. Complete clinical information was available for 541 patients.
Test set (n = 168) was obtained from an independent group of patients enrolled in the
Danish DBCG 82 b and c breast cancer studies [13,14]. All tumors in the training and
test sets were collected by excision during their primary surgery. Tumor content was
verified by histopathology. The third set consisted of 256 FNAs obtained from primary
breast cancers prior to NST of which 132 belonged to patients who subsequently
received uniform taxane and anthracycline-based NST at MDACC (12 cycles of weekly
paclitaxel or 4 cycles of every 3-week docetaxel, followed by 4 cycles of FAC or
FEC100). All tissues were collected under Institutional Review Board-approved labora-
tory protocols.
Tumors were characterized for ER and PR status by immunohistochemistry (IHC),
ligand-binding dextran-coated charcoal assay or reverse phase protein lysate array
(RPPA). ER/PR positivity was designated when nuclear staining occurred in ≥10% of
tumor cells, with ligand binding of ≥ 10 fmol/mg, or with a log2 mean centered cutoff
of -1.48(ER) or +0.52(PR) by RPPA. Hormone receptor (HR) positivity was designated
when either ER or PR was positive. HER2 status was assessed by IHC, fluorescent in
situ hybridization (FISH) or RPPA. HER2 positivity was designated when 3+
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membranous staining occurred in ≥10% of tumor cells, with a HER2/CEP17 ratio of >
2.0 or with a log2 mean centered cutoff of +0.82 by RPPA [15].
Reverse phase protein lysate microarray (RPPA)
RPPA was completed independently and at different time points for training and tests
sets using individual arrays. Protein was extracted from human tumors and RPPA was
performed as described previously [16-19]. Lysis buffer was used to lyse frozen tumors
by homogenization (excised tumors) or sonication (FNAs). Tumor lysates were nor-
malized to 1 μg/μL concentration as assessed by bicinchoninic acid assay (BCA) and
boiled with 1% SDS. Supernatants were manually diluted in five-fold serial dilutions
with lysis buffer. An Aushon Biosystems 2470 arrayer (Burlington, MA) created 1,056
sample arrays on nitrocellulose-coated FAST slides (Schleicher & Schuell BioScience,
Inc.). Slides were probed with 146 validated primary antibodies (Additional File 1,
Table S1) and signal amplified using a DakoCytomation-catalyzed system. Secondary
antibodies were used as a starting point for amplification. Slides were scanned, ana-
lyzed, and quantified using Microvigene software (VigeneTech Inc., Carlisle, MA) to
generate spot signal intensities, which were processed by the R package SuperCurve
(version 1.01) [18], available at “http://bioinformatics.mdanderson.org/OOMPA“. A
fitted curve ("supercurve”) was plotted with the signal intensities on the Y-axis and the
relative log2 concentration of each protein on the X-axis using the non-parametric,
monotone increasing B-spline model [18]. Protein concentrations were derived from
the supercurve for each lysate by curve-fitting and normalized by median polish. Pro-
tein measurements were corrected for loading as described [15-17,19]. For the selec-
tion of the 146 antibody set, we focused on markers currently used for breast cancer
classification due to their value in treatment decisions (ER, PR, HER2). We then added
additional antibodies to targets implicated in breast cancer pathophysiology, followed
by antibodies to targets implicated in the pathophysiology of other cancer lineages.
Final selection of antibodies was also driven by the availability of their high quality
that could pass a strict validation process as previously described [20].
Statistical Methods
Detailed statistical methods are described in Additional File 2.
Identification of Prognostic Groups
To develop a set of markers for breast cancer classification and outcomes prediction,
we used a hypothesis-driven approach, selecting markers according to their functional
assignments and subsequently performing supervised proteomic clustering analysis to
optimize the selection of groups with the most distinct recurrence-free survival (RFS)
outcomes. We hypothesized that three functions would strongly affect the behavior
and therapy responsiveness in breast cancer: ER function, grade/proliferation, and
receptor tyrosine kinase activity. From the initial 146 antibodies, we selected markers
within these three functional categories. We tested multiple combinations requiring
that a minimum of one marker per functional category remain in each model. Unsu-
pervised clustering analysis, using the uncentered correlation distance metric [21] and
Ward’s linkage rule [22], was applied to the training set to define groups and allow
correlation with previously defined breast cancer subtypes. We then visualized the RFS
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curves to select the marker set that was associated with the clearest differences in RFS
between the groups identified in the training set. Because of multiple testing and the
possibility of false discovery, this model was locked and then applied to an independent
test set to which the statistical analysis team was kept blinded. The selected protein
groups were as follows: ER function (ER, ERpS118, ERpS167, PR, AR, EIG121, Bcl2,
GATA3, IGF1R, and IGFBP2), grade/proliferation (CCNB1, CCND1, CCNE1, CCNE2,
and PCNA), and receptor tyrosine kinase activity (cKit, EGFR, EGFRp1045, EGFRp922,
HER2, HER2p1248, FGFR1, FGFR2, IGF1R, IGFRpY1135/Y1136).
RFS was estimated according to the Kaplan-Meier method and compared between
groups using the log-rank statistic. Cox proportional Hazard Models were fitted using
proteomic subgroups, selected markers and clinical variables.
Decision trees
We constructed a statistical model to predict the classes discovered by hierarchical clus-
tering using a binary decision tree with a logistic regression model at each node. The
split at each node was a union of two of the classes. Protein-by-protein two-sample t-
tests between the two halves of the split were computed. The proteins were ordered by
p-value and then added one at a time into a logistic regression model until the desired
prediction accuracy was achieved. In order to avoid overfitting data, a default precision
accuracy of 95% was set for each node. Finally, the Akaike Information Criterion (AIC)
was used to eliminate redundant terms from the logistic regression model [23].
Validation of Prognostic Groups for RFS
The coefficients of the model, which used logistic regression at each node of a decision
tree to place samples in one of six classes (or prognostic groups) were finalized and
locked. An implementation of the model was provided to an independent analyst,
along with the class predictions. The independent analyst was provided with the
unblinded clinical data after implementation of the model. Cox proportional hazards
models were then constructed using the predicted classes as covariates to test their
association with RFS.
Validation of Prognostic Groups for pCR
We applied the algorithm to the last sample set (132 FNAs) and correlated the groups
with response to NST. We clustered the samples as above and compared these clusters
to the class labels predicted by the decision tree model with Cohen’s kappa statistic
[24,25]. Using the predicted prognostic groups, we developed a Bayesian model to esti-
mate the posterior probability of pCR in each group. We modeled the pCR rates as
coming from a beta-binomial distribution [26].
Development of a Prognostic Score and its Application to Prediction of pCR
We next converted the six prognostic groups into a continuous prognostic score (PS)
by fitting an ordinal regression model on the training set [27]. PS is a weighted linear
combination of the relative protein concentration of the markers:
PS = -0.2841*ER - 1.3038*PR + 0.0826*Bcl2 -0.6876*GATA3 + 0.5169*CCNB1 +
0.1000*CCNE1 + 0.4321*EGFR + 0.5564*HER2 + 0.8284*HER2p1248 +
0.2424*EIG121.
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We used this formula to compute PS on the test set; PS was associated with RFS
estimates by the Cox proportional hazards model. We also used the same formula to
compute PS on the NST treated FNA set. We fitted a logistic regression model using
the NST response as the binary response variable (pCR vs. residual disease) and PS as
a predictor. The prediction of response was evaluated by a receiver operating charac-
teristics (ROC) curve.
Models for Recurrence-Free Survival and Likelihood of Pathologic Complete Response
A Cox proportional hazards model to estimate association with RFS was fit using each
of the following covariates: prognostic group, tumor size, histologic grade, node status,
each of the 10 protein markers, and PS. Using the same covariates, a logistic regression
model was fit to estimate the association of each covariate with pCR. Stepwise multi-
variate model selection [28,29] was used to determine the combination of covariates
for the multivariate models.
All statistical analysis was performed in R 2.8.1. (R Development Core Team (2008).
R: A language and environment for statistical computing (R Foundation for Statistical
Computing, Vienna, Austria). http://www.R-project.org.
Results
Unsupervised Proteomic Clustering
Table 1 summarizes the clinical characteristics of each set. Training set (n = 712) was
analyzed for 146 proteins (Additional File 1, Table S1) using RPPA. Proteins were cho-
sen based on a literature search of important targets and proteomic processes in breast
cancer for which robust antibodies binding to a single or dominant band on western
blotting could be identified and validated for RPPA as described [1-3,30-32]. Unsuper-
vised clustering of the proteomic profiles is shown in Additional file 1: Figure S1. The
146 proteins stratified breast cancers into six major groups with different RFS out-
comes (Additional file 1: Figure S2). The six groups included a predominantly HER2-
positive group, a HR-negative and HER2-negative (triple receptor-negative) group with
poor outcomes, a HR-positive group with a good outcome and three groups with inter-
mediate outcome: an HR group with overexpression of proteins including cyclins B1
and E1 as well as components of the protein synthesis machinery including phosphory-
lated S6 ribosomal protein and 4EBP1, a group with overexpression of stromal markers
including collagen VI, CD31 and caveolin1, and a group defined by up-regulation of a
large number of proteins and phospho-proteins in several mechanistic pathways.
Supervised Proteomic Clustering
The hypothesis-driven approach described in Methods was applied to the training set
and identified 10 markers in three functional groups known to be important to breast
cancer behavior: ER function (ER, PR, Bcl2, GATA3, EIG121), tyrosine kinase receptor
function (EGFR, HER2, HER2p1248), and cell proliferation (CCNB1, CCNE1). These
markers separated the breast cancers into six subgroups (PG1 to 6) with markedly dif-
ferent RFS outcomes, (Log-rank p = 8.8 E-10), (Figures 1A and 1D). A decision tree
model was developed (Figure 1C) that recovered the six subgroups of breast tumors
identified by clustering with the 10 markers with an overall accuracy of 89%. Full
description of the model is presented in Additional File 3. We then confirmed the
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Table 1 Clinical characteristics of all sets
Characteristic Training
(n = 712)
Test
(n = 168)
FNA
(n = 256)
FNA subgroup
(n = 132)
Age
Median 62 56 50 50
Range 23-89 30-69 23-85 23-77
T stage (n = 542) (n = 166) (n = 255) (n = 132)
Tis 6 0 5 0
T1 165 49 22 14
T2 268 97 135 76
T3 37 20 42 24
T4 66 0 51 18
N stage (n = 541) (n = 166) (N = 255) (n = 132)
N0 280 0 102 47
N1 198 11 84 52
N2 39 75 15 13
N3 24 80 54 20
Stage (n = 541) (n = 166) (n = 254) (n = 132)
0 6 0 2 0
I 105 1 8 4
II 315 83 141 79
III 94 82 86 49
IV 21 0 18 0
Histology (n = 576) (n = 166) (n = 255) (n = 132)
Ductal 446 132 212 113
Other 130 34 43 19
Grade (n = 457) (n = 132) (n = 251) (n = 132)
1 65 29 12 8
2 149 69 72 39
3 243 34 167 85
Estrogen Receptor Status (n = 709) (n = 165) (n = 255) (n = 132)
Positive 447 126 149 79
Negative 262 39 106 53
Progesterone Receptor Status (n = 709) (n = 168) (n = 255) (n = 132)
Positive 336 82 108 56
Negative 373 86 147 76
HER2 Status (n = 709) (n = 128) (n = 254) (n = 132)
Positive 142 18 53 121
Negative 567 110 201 11
Clinical Subtype (n = 709) (n = 128) (n = 254) (n = 132)
Hormone receptor-positive 383 106 139 80
HER2-positive 142 40 53 11
Triple receptor-negative 184 22 62 41
Systemic Treatment (n = 598) (n = 168) (n = 255) (n = 132)
Adjuvant hormonal therapy 341 97 136 78
(Neo)Adjuvant chemotherapy 188 71 253 132
CMF-based 188 71 0 0
Anthracycline-based 0 0 21 0
Taxane-based 0 0 14 0
Anthracycline and Taxane-
based
0 0 184 132
Trastuzumab-based 0 0 34 0
None 111 0 2 0
Note that numbers may not add up to the total in each category due to missing data. Tumors are assigned to the
HR-positive group only if they are HER2-negative; tumors that are HER2-positive and HR-positive are classified in the
HER2-positive group. FNA: Fine needle aspirates.
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presence of the six subgroups as well as their RFS in an independent test set, (Log-
rank p = 0.0013), (Figures 1B and 1E). Table 2 summarizes the 5-year RFS estimates
for each of the prognostic groups in the training and test sets.
We applied this classification approach to 256 FNAs from MDACC. In order to con-
firm that the same clusters were present, we compared the patient groups obtained by
direct hierarchical clustering of the 256 FNA samples to the prognostic groups pre-
dicted in the FNA samples by the decision tree model derived from the training set
(Cohen’s  = 0.70, p < 1E-20). The decision tree predictions were also applied to the
subset of 132 FNAs from patients who received uniform anthracycline and taxane-
based NST, and the same six clusters were found (Cohen’s  = 0.66, p value < 1E-20,
Figure 2A). The association between pCR rates and the (predicted) prognostic groups
did not quite reach statistical significance (c2 = 10.3076 on 5 degrees of freedom; p =
0.067). However, a Bayesian analysis of the pCR rates indicated that there was at least
a 70% posterior probability that groups PG2 and PG3 have pCR rates at least 5% lower
than those in PG4 or PG6 (Figure 2B).
Prognostic Score Predicts pCR
As described in Methods, we computed a continuous prognostic score (PS) based on
the grouping defined in the training set. A Cox proportional hazards model on the
training set (CoxTrain) using PS to predict RFS was significant (Wald test; coefficient
= 0.128, p = 3.2E-13). A second Cox model, fit on the test set (CoxTest), was also sig-
nificant (Wald test; coefficient = 0.084, p = 1.1E-05) (Figure 3A). Of 132 patients who
received anthracycline-taxane-based NST, 32 (24%) had a pCR. We computed the
prognostic score PS for each FNA sample; the values ranged from -8.16 to 10.16. A
C D E
A B
P=8.8E-10 P=0.0013
Training Test
Figure 1 Supervised clustering of breast cancers with quantification data for 10 proteins derived
using reverse phase protein arrays. The 712 breast tumor samples (Training set, 1A) were clustered with
the 10 markers using an “uncentered correlation” distance metric along with the Ward linkage rule. This
analysis yielded six subgroups (BG1-6). The 168 breast tumor samples (Test set, 1B) were subgrouped into
one of 6 groups (PG1-6) using the decision tree (1C) that was derived from the training set. Patients in the
six subgroups differed significantly in their recurrence-free survival in both training (1D) and test (1E) sets.
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logistic regression model showed that PS was also significantly associated with pCR (p
= 0.0021, Figure 3B). Further, an unequal variance t-test comparing the prognostic
scores between patients with pCR and residual disease also revealed a significant differ-
ence between mean scores (p = 0.00024 Figure 3C). The area under the curve (AUC)
in a ROC curve analysis was 0.7 with a specificity of 98% and a negative predictive
value of 76% (Figure 3D).
Models for Recurrence-Free Survival and Likelihood of Pathologic Complete Response
Univariate models for RFS (Cox proportional hazards on the test set; CoxTest) and
pCR (logistic regression on the uniformly treated FNA dataset; LR-FNA) are
Table 2 Five-year DFS estimates for each of the prognostic groups in both the training
and test sets
5-year Recurrence-Free Survival Estimates Training Set
Median follow-up 42.23 months (1.45-246.40 months)
No. at Risk No. of Events 5-Year Estimate 95% Confidence Interval P-Value
All 446 106 0.699 (0.65, 0.751)
Prognostic Group 1 108 17 0.809 (0.730, 0.896)
Prognostic Group 2 84 7 0.876 (0.793, 0.968)
Prognostic Group 3 44 8 0.758 (0.620, 0.926)
Prognostic Group 4 73 22 0.595 (0.464, 0.763)
Prognostic Group 5 109 36 0.576 (0.472, 0.703)
Prognostic Group 6 28 16 0.299 (0.152, 0.589) 8.88E-10
5-year Recurrence-Free Survival Estimates Test Set
Median follow-up 217 months (180-259 months)
No. at Risk No. of Events 5-Year Estimate 95% Confidence Interval P-Value
All 166 92 0.446 (0.376, 0.528)
Prognostic Group 1 33 18 0.455 (0.313, 0.661)
Prognostic Group 2 45 17 0.622 (0.496, 0.781)
Prognostic Group 3 15 5 0.667 (0.466, 0.953)
Prognostic Group 4 22 16 0.273 (0.138, 0.540)
Prognostic Group 5 20 14 0.300 (0.154, 0.586)
Prognostic Group 6 31 22 0.290 (0.167, 0.503) 0.0013
A B
Figure 2 The 132 fine needle aspirates from patients who received anthracycline and taxane-based
neoadjuvant systemic therapy were subgrouped into one of the 6 groups using the decision tree
from the training set. Six true patient groups were obtained (2A), Cohen’s kappa score = 0.66. Beta-
binomial distribution and computed joint posterior probabilities were used to evaluate the association of
the prognostic groups with pCR, the posterior distribution estimates of pCR by prognostic group are
shown in 2B.
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summarized in Table 3. All clinical and molecular variables, except for EGFR, were sig-
nificantly associated with RFS. The addition of the prognostic score to the model with
clinical covariates reduced the residual deviance with a X21 = 2.96, p = 0.09. Stepwise
model selection using AIC retained all clinical covariates and the prognostic score for
the final model:
log(h(t)/h0(t)) = 0.414Size + 1.34Node + 0.803Grade + 0.070PrognosticScore.
For response (pCR vs. residual disease), grade was the only clinical covariate signifi-
cantly associated with response. All protein markers except EGFR, HER2, pHER21248
and EIG121 were significantly associated with response. The addition of the prognostic
score to grade reduced residual deviance with a X21 = 5.39, p = 0.02. Stepwise model
selection using AIC showed that both grade and prognostic score were retained in the
final model:
logit(pCR) = -2.61 + 0.902Grade + 0.2210PrognosticScore.
We compared ROC curves for predicting pCR by the prognostic scores and the step-
wise selected model and found that AUC, as well as the specificity and negative
DC
BA
p=0.00024 
Figure 3 A ten-protein prognosis score by ordinal regression modeling was derived from the
training set. 3A. Probability of recurrence as a continuous function of the score. The rug plot shows the
prognosis score for individual patients in the study. Dashed curves indicate the 95 percent confidence
intervals. 3B. Probability of pCR as a function of the prognostic score. 3C. Stripcharts showing the level of
prognostic score by response to anthracycline and taxane-based neoadjuvant systemic therapy. 3D.
Receiver operating characteristics curves for the performance of the prediction of pCR versus residual
disease by the logistic model using the prognostic score. AUC: area under the curve.
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Table 3 Models for Recurrence-Free Survival and likelihood of pathological complete
response
RFS pCR
Univariate Models
Variable Hazard
Ratio
95% CI Log-rank
P-value
Odds
Ratio
95% CI Wald’s
P-Value
Prognostic Group 1 1.59 (.87, 2.90) 3.54 (.06, 28.14)
Prognostic Group 2 1.00 (1.0, 1.0) 1.00
Prognostic Group 3 1.15 (.51, 2.60) 2.16 (.32, 17.82)
Prognostic Group 4 3.12 (1.64, 5.90) 7.19 (1.77, 48.89)
Prognostic Group 5 3.01 (1.67, 5.41) 4.24 (.90, 30.76)
Prognostic Group 6 7.00 (3.53,
13.86)
<.0001 11.50 (1.40,
123.05)
.0519
Tumor size (</ = 2 cm vs. >
2 cm)
1.85 (1.16, 2.96) .0094 1.30 (.56, 2.94) .5364
Node status (positive vs.
negative)
2.93 (1.99,4.29) <.0001 1.11 (.50, 2.56) .7981
Histologic grade (1 and 2 vs.
3)
3.70 (2.45, 5.60) <.0001 4.35 (1.67, 13.62) .0052
ER 0.82 (.76, .88) <.0001 .73 (.56, .93) .0180
PR 0.75 (.66, .85) <.0001 .67 (.45, .91) .0235
Bcl2 0.75 (.65, .86) <.0001 .63 (.39, .96) .0435
GATA3 0.77 (.66, .90) .0010 .58 (.33, .95) .0411
CCNB1 1.23 (1.12, 1.36) <.0001 1.32 (1.00, 1.76) .0449
CCNE1 1.40 (1.11, 1.76) .0039 2.52 (1.32, 5.05) .0062
EGFR 1.04 (.81,1.36) .7437 1.54 (.90, 2.88) .1333
HER2 1.21 (1.08, 1.36) .0015 1.37 (.72, 2.57) .3253
HER2p1248 1.18 (1.11, 1.26) <.0001 1.09 (.74, 1.56) .6528
EIG121 0.389 (.29, .52) <.0001 .53 (.26, 1.05) .0712
Prognostic score
(continuous)
1.14 (1.10, 1.18) <.0001 1.32 (1.12, 1.61) .0021
Multivariate Models
Variable Hazard
Ratio
95% CI Log-rank
P-value
Odds
Ratio
95% CI Wald’s
P-Value
Clinical Characteristics
Model
1.87E-12* .021*
Size 1.63 (.94, 2.85) .0836 1.10 (.45, 2.63) .8237
Node 3.90 (2.25, 6.75) <.0001 1.07 (.56, 2.58) .8732
Grade 2.75 (1.55, 4.85) .0005 4.29 (1.64, 13.51) .0057
Clinical Model +
Prognostic Score
2.48E-12* .004*
Size 1.51 (.86, 2.65) .1489 1.18 (.47, 2.88) .7192
Node 3.83 (2.22, 6.61) <.0001 1.02 (.42, 2.51) .9657
Grade 2.23 (1.21, 4.13) .0106 2.41 (.80, 8.27) .1332
Prognostic score 1.07 (.99, 1.16) .0895 1.24 (1.03, 1.52) .0327
Tumor Grade + Prognostic
Score
.01*
Grade 2.46 (.83, 8.40) .1198
Prognostic score 1.23 (1.03, 1.51) .0283
RFS: Recurrence-free survival; pCR; pathologic complete response. * X2 test.
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predictive values were the same (0.7, 98% and 76% respectively), suggesting that the
prognostic score may be a more powerful predictor than clinical information.
Discussion
We have identified and validated a 10-protein panel that accurately and reproducibly
classifies patients with breast cancer into six subgroups with significantly different 5-
year RFS times. These six groups included two HR positive groups differentiated pri-
marily by PR levels with the PR high group having the best outcome, a HER2, pHER2
and EGFR positive group with the worst outcome (pre-trastuzumab treatment) and
three triple negative groups, one with high cyclins and two groups without well defined
selectors. Further, in an independent set of FNAs from patients who underwent NST,
we were able to reproduce this classification and to use it to predict response to
neoadjuvant anthracycline and taxane-based therapy. Further, in three independent
sets, the 10-protein signature had a higher predictive value than clinical variables
including tumor size, nodal status and grade in Cox models for RFS and in a logistic
regression model to predict pCR.
Several studies using transcriptional profiling have classified breast cancer into differ-
ent subtypes with implications in patient prognosis [1,30-32], frequency of genomic
alterations [33,34], and therapy response [31,35,36]. Since proteins are the immediate
effectors of cellular behavior, interrogation of the functional proteome is likely to com-
plement data derived from transcriptional profiling. Thus, the integrated study of the
expression and activation of multiple proteins and signaling pathways has the potential
to provide powerful classifiers and predictors in breast cancer. As protein levels and
function depend not only on translation but also on post-translational modifications,
functional proteomic profiling may theoretically yield more direct answers to func-
tional and pharmacological questions than transcriptional profiling alone. However,
practical, high-throughput approaches to the study of the functional proteome have
not been available until recently. RPPA is a useful tool to identify and validate protein
and phospho-proteins [19-23]. Our data suggest that RPPA has the potential to
advance our understanding of breast cancer biology and to aid in the identification and
validation of useful biomarkers. Our findings validate the importance of ER, PR and
HER2. However, seven additional markers including other tyrosine kinase receptors
and proliferation markers involved in therapy resistance (EGFR, CCNB1, CCNE1) are
part of the 10-protein panel. The combination of 10 markers and the power of the 10
markers as compared to ER/PR and HER2 is novel. The ER, PR and HER2 and the
proliferation markers correspond to other breast cancer classifiers such us the intrinsic
subtypes or the Oncotype DX Recurrence Score which have also shown that ER, HER2
and proliferation are the most important classifiers, prognostic and predictive markers
in breast cancer [1,31]. This demonstrates that RPPA can capture prognostic and pre-
dictive differences associated with breast cancer subtypes.
Several factors are important in selection and validation of biomarkers: The analysis
platform must be sufficiently robust to detect subtle changes between tumors. Sample
sets must be robust enough to reduce pre-analytical data biases and must reflect the
intended use of the marker or marker set. Independent sample sets must be used to
validate the prognostic and predictive power of biomarkers particularly when many
biomarkers are assessed on small sample sets. Lastly, bioinformatics support is essential
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at all steps in any project. The current study has satisfied all of the requirements men-
tioned above. RPPA is a robust platform able to detect minimal changes in protein
levels [15]. Three large independent sample sets with adequate clinical and outcome
information were used for training and testing. Bioinformaticians were closely involved
in study design as well as data analyses.
Our findings also have limitations. Patient cohorts received diverse types of systemic
treatments and limiting the ability to dissect effects on prognosis from variables that
predict endocrine and/or chemotherapy sensitivity. When looking at pCR predictors,
all prognostic signatures can reasonably predict pCR, however patients predicted to
obtain pCR may have significantly worse survival than those predicted not to respond
due to different prognostic variables i.e. HR positivity. So, if our signature is primarily
prognostic, its potential utility for selecting chemotherapy sensitivity would be limited;
for this reason, validation studies in independent cohorts are needed.
The issues of tumor heterogeneity and the utility of laser captured microdissection
were considered in our previous work focusing on the technical assessment of the uti-
lity of RPPA for the study of the functional proteome in non-microdissected human
breast cancers [20]. This approach used captures information contained in the tumor
cells, the stroma and in particular the tumor stroma interaction. The approach of
using the complete tumor including interactions of tumor and stroma to classify
patients and predict outcomes is the basis for the current transcriptional profiling
approaches such as Oncotype Dx or Mammaprint. We have attempted to develop and
implement RPPA approaches on microdissected tumors. However, due to a number of
technical challenges, this approach is not as robust as study of complete tumors which
captures information from the tumor and the stroma as well as tumor stroma
interactions.
In summary, we have developed a 10-protein biomarker panel that may have poten-
tial utility in the management of patients with breast cancer. Today, it is clear that we
should view breast cancer as several distinct diseases. Thus, further work is needed to
identify predictors of response to individual therapies that target different clinical and
molecular subgroups of breast cancer.
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